Amgen Q1 2025 Update: Financials and Product Performance
Ticker: AMGN · Form: 10-Q · Filed: May 2, 2025 · CIK: 318154
Sentiment: neutral
Topics: financials, earnings, debt, biotech
Related Tickers: AMGN
TL;DR
Amgen Q1 2025: Revenue up, debt stable, key product sales detailed.
AI Summary
Amgen Inc. reported its first quarter 2025 results for the period ending March 31, 2025. The company's financial statements include details on common stock, A2.00 Senior Notes Due 2026, and product revenues for the first quarter of 2025 and 2024. Key balance sheet figures as of March 31, 2025, and December 31, 2024, are also presented, including common stock, retained earnings, and accumulated other comprehensive income.
Why It Matters
This filing provides investors with a snapshot of Amgen's financial health and revenue generation from its products in early 2025, crucial for assessing the company's ongoing performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine quarterly financial filing with no immediate red flags or significant negative developments indicated.
Key Numbers
- 2025-03-31 — End of Q1 2025 (Reporting period end date)
- 2024-12-31 — End of Q4 2024 (Prior period balance sheet date)
- 2025-01-01 — Start of Q1 2025 (Reporting period start date)
Key Players & Entities
- AMGEN INC (company) — Filer
- 20250331 (date) — Period of Report
- 20250502 (date) — Filed as of Date
- A2.00 Senior Notes Due 2026 (dollar_amount) — Debt Instrument
FAQ
What were Amgen's product revenues for the first quarter of 2025 compared to the first quarter of 2024?
The filing indicates product revenues for the period January 1, 2025, to March 31, 2025, and compares them to the period January 1, 2024, to March 31, 2024.
What is the principal amount of the A2.00 Senior Notes Due 2026?
The filing references the 'A2.00 Senior Notes Due 2026' for the period January 1, 2025, to March 31, 2025, but the specific principal amount is not detailed in the provided text.
What are the key components of Amgen's equity as of March 31, 2025?
As of March 31, 2025, Amgen's equity includes common stock, retained earnings, and accumulated other comprehensive income, with specific values detailed for December 31, 2024, and implied for March 31, 2025.
What is Amgen's fiscal year end?
Amgen's fiscal year ends on December 31.
What is the filing date for this 10-Q report?
This 10-Q report was filed as of May 2, 2025.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 2, 2025 regarding AMGEN INC (AMGN).